Early Remdesivir Linked to Better Kidney Transplant Outcomes

Key Takeaways

• Kidney transplant recipients with symptomatic COVID-19 who initiated remdesivir within 7 days was associated with a lower 1-year risk of graft failure or death versus no remdesivir.
• Early remdesivir was also associated with a lower risk of cardiovascular events. Separately, the investigators said the graft failure-or-death association was generally consistent across clinically relevant subgroups.
• In the weighted analysis, early remdesivir was not clearly associated with lower all-cause mortality alone or long COVID.

The study published in JAMA Network Open used retrospective observational data from five Johns Hopkins Health System hospitals to emulate a target trial and applied a clone-censor-weight approach. The cohort included 432 kidney transplant recipients with symptomatic COVID-19 and functioning allografts from March 2020 through January 2024; 41% initiated remdesivir within 7 days of diagnosis and completed at least 3 consecutive days of therapy, while patients who received anti-SARS-CoV-2 monoclonal antibodies, nirmatrelvir-ritonavir, or molnupiravir were excluded. A majority of infections (60.2%)occurred during the Omicron period, with the remainder distributed across pre-Delta and Delta waves.

Remdesivir started within 7 days of COVID-19 diagnosis was associated with a 47% lower 1-year risk of graft failure or death (HR 0.53; 95% CI 0.31-0.92) among kidney transplant recipients with symptomatic infection. The analysis also linked early treatment with a lower risk of cardiovascular events (HR 0.58; 95% CI 0.35-0.98). Early remdesivir treatment was not significantly associated with lower risk of all-cause mortality (HR 0.51; 95% CI 0.24-1.06) or long COVID (HR 0.65; 95% CI 0.21-2.05).

This study helps address an important evidence gap by evaluating early remdesivir use in kidney transplant recipients, a population that has been underrepresented in pivotal antiviral trials despite remaining at high risk for severe COVID-19 because of chronic immunosuppression, impaired vaccine responses, and multiple comorbidities. The findings also provide additional real-world data in a setting where concerns have persisted regarding potential nephrotoxicity and interactions with immunosuppressive therapies such as tacrolimus.

Clinician Questions

What was the reported 1-year graft outcome with remdesivir started within 7 days in kidney transplant recipients with COVID-19?

Investigators reported a 47% lower risk of graft failure or death at 1 year versus no remdesivir among 432 kidney transplant recipients with symptomatic COVID-19, with HR 0.53 (95% CI 0.31-0.92). This finding came from an observational target trial emulation rather than a randomized comparison.

How was early remdesivir defined in the Johns Hopkins kidney transplant COVID-19 analysis?

Early remdesivir in the Johns Hopkins kidney transplant COVID-19 analysis meant initiation within 7 days of COVID-19 diagnosis with at least 3 consecutive days of therapy. In that cohort, 41% of kidney transplant recipients with symptomatic COVID-19 received early remdesivir, and the comparison group received no remdesivir.

Did early remdesivir in kidney transplant recipients with COVID-19 show associations beyond graft outcomes?

Early remdesivir in kidney transplant recipients with COVID-19 was associated with a 42% lower risk of cardiovascular events, with HR 0.58 (95% CI 0.35-0.98), while the weighted analysis did not show a clear lower risk for all-cause mortality alone, HR 0.51 (95% CI 0.24-1.06), or long COVID, HR 0.65 (95% CI 0.21-2.05). The investigators described the long COVID result as limited by few events.